CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 58 enrolled
Drug / intervention
tivozanib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01782313
NCT01782313Phase 2Completed

A Phase II Study of Tivozanib in Patients With Metastatic and Non-resectable Soft Tissue Sarcomas

Northwestern University·interventional·Posted Feb 1, 2013·Updated Sep 9, 2019

In Brief

A Phase 2 clinical trial evaluating tivozanib and laboratory biomarker analysis for Recurrent Adult Soft Tissue Sarcoma and 2 related conditions. Completed, enrolled 58 participants across 5 sites.

Detailed Summary

This study is for patients who have been diagnosed with soft tissue sarcoma that has spread (metastasized) or that is not eligible for removal by surgery. The purpose of this study is to determine how soft tissue sarcomas respond to treatment with an investigational drug called tivozanib. In some lab and clinical studies, tivozanib has been shown to interfere with the growth of some types of tumors. The study will also evaluate how safe the study treatment is by observing how many and what kind of adverse events (side effects) participants experience.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedFeb 1, 2013
Enrollment StartMar 6, 2013
Primary CompletionMay 27, 2015
Study CompletionDec 28, 2016
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 13.4 years ago

Interventions

tivozanibdrug

Given PO

laboratory biomarker analysisother

Correlative studies